Paper42638735
Tuberculosis: insights into latency, treatment strategies, and the potential roles of metronidazole.
Wiker HG. Front Tuberc, 2023. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Tuberculosis: insights into latency, treatment strategies, and the potential roles of metronidazole. Papers, record 42638735. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42638735
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tuberculosis: insights into latency, treatment strategies, and the potential roles of metronidazole.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27296510 | Substantial molecular evolution and mutation rates in prolonged latent Mycobacterium tuberculosis infection in humans. | Int J Med Microbiol | 2016 | https://conductscience.org/library/papers/27296510 | PubMed |
| 2 | 21364979 | Analysis of the lung microbiome in the "healthy" smoker and in COPD. | PLoS One | 2011 | https://conductscience.org/library/papers/21364979 | PubMed |
| 3 | 21315848 | How dormant is Mycobacterium tuberculosis during latency? A study integrating genomics and molecular epidemiology. | Infect Genet Evol | 2011 | https://conductscience.org/library/papers/21315848 | PubMed |
| 5 | 10223954 | Metronidazole therapy in mice infected with tuberculosis. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10223954 | PubMed |
| 6 | 8675308 | An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. | Infect Immun | 1996 | https://conductscience.org/library/papers/8675308 | PubMed |
| 7 | 9755928 | Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. | Int J Tuberc Lung Dis | 1998 | https://conductscience.org/library/papers/9755928 | PubMed |
| 8 | 23733467 | Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23733467 | PubMed |
| 9 | 21680950 | Topographical continuity of bacterial populations in the healthy human respiratory tract. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/21680950 | PubMed |
| 10 | 4903501 | Controlled chemoprophylaxis trials in tuberculosis. A general review. | Bibl Tuberc | 1970 | https://conductscience.org/library/papers/4903501 | PubMed |
| 11 | 21575291 | Long-term course of Mycobacterium tuberculosis infection in Swedish birth cohorts during the twentieth century. | Int J Tuberc Lung Dis | 2011 | https://conductscience.org/library/papers/21575291 | PubMed |
| 12 | 17242153 | Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17242153 | PubMed |
| 13 | 27780211 | The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. | PLoS Med | 2016 | https://conductscience.org/library/papers/27780211 | PubMed |
| 14 | 18491971 | Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. | J Infect Dis | 2008 | https://conductscience.org/library/papers/18491971 | PubMed |
| 15 | 356255 | Bovine tuberculosis in man--reinfection or endogenous exacerbation. | Scand J Respir Dis | 1978 | https://conductscience.org/library/papers/356255 | PubMed |
| 16 | 11807725 | Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. | J Infect Dis | 2002 | https://conductscience.org/library/papers/11807725 | PubMed |
| 17 | 30139910 | Revisiting the timetable of tuberculosis. | BMJ | 2018 | https://conductscience.org/library/papers/30139910 | PubMed |
| 18 | 24618815 | Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. | PLoS One | 2014 | https://conductscience.org/library/papers/24618815 | PubMed |
| 19 | 9805839 | Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. | Indian J Med Res | 1998 | https://conductscience.org/library/papers/9805839 | PubMed |
| 20 | 22895789 | Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22895789 | PubMed |
| 21 | 2632532 | Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. | J Assoc Physicians India | 1989 | https://conductscience.org/library/papers/2632532 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42638735
GET https://conductscience.org/api/papers/v1/42638735/references?page=2